Smaller vial for Alzheimer’s drug could save Medicare $366M per year: Study

A new study suggests that Medicare could save up to $366 million annually by introducing a new vial size for Alzheimer’s drug lecanemab, which is currently only available in single-use, 500- and 200-milligram vials. 

Advertisement

The study, published in JAMA Internal Medicine Oct. 14 by researchers at the David Geffen School of Medicine at University of California in Los Angeles, revealed that weight-based dosing results in substantial medication waste of up to an estimated 5.8%. 

The study analyzed data from older adults with Medicare Part B coverage, showing that discarded medication from just 16 patients could supply enough for an additional person. 

Lead author, medical student Frank Zou, emphasized the importance of reducing waste, noting that Medicare spent $33 billion on Part B infusion drugs in 2021. Researchers found that by adding a 75-milligram vial, waste could be reduced by 74% without a compromise to patient care. 

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

The Performance Gap Your Pharmacy Training Metrics Can’t See

Monday, August 10
12:00 PM - 1:00 PM CDT

Presenters: Michael Alexander, AudirieDr. Tina Moen, PharmD, Colibri Healthcare

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.